Biogen partners with Quintiles to beef up its clinical development processes

The companies begin a 5-year strategic clinical development agreement to increase Biogen Idec's (BIIB) clinical trial efficiency. A dedicated Quintiles (Q) team will work on the design, planning and execution of Biogen's Phase 2, 3 and 4 clinical trials and a select number of Phase 1's.

Biogen will leverage Quintiles' technology and systems across its portfolio of products.

No financial terms are disclosed.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs